[Federal Register: May 25, 1999 (Volume 64, Number 100)]
[Notices]               
[Page 28214]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr25my99-105]

-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

 
Importation of Controlled Substances; Notice of Application

    Pursuant to section 1008 of the Controlled Substance Import and 
Export Act (21 U.S.C. 958(i)), the Attorney General shall, prior to 
issuing a regulation under this Section to a bulk manufacturer of a 
controlled substance in Schedule I or II and prior to issuing a 
regulation under section 1002(a) authorizing the importation of such a 
substance, provide manufacturers holding registrations for the bulk 
manufacture of the substance an opportunity for a hearing.
    Therefore, in accordance with Sec. 1301.34 of Title 21, Code of 
Federal Regulations (CFR), notice is hereby given that on March 2, 
1999, Research Biochemicals, Limited Partnership, 1-3 Strathmore Road, 
Natick, Massachusetts 01760, made application by renewal to the Drug 
Enforcement Administration to be registered as an importer of the basic 
classes of controlled substances listed below:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Cathinone (1235)...........................  I
Methcathinone (1237).......................  I
Aminorex (1585)............................  I
Methaqualone (2565)........................  I
Alpha-Ethyltryptamine (7249)...............  I
Ibogaine (7260)............................  I
Lysergic acid diethylamide (7315)..........  I
Marihuana (7360)...........................  I
Tetrahydrocannabinols (7370)...............  I
Mescaline (7381)...........................  I
Bufotenine (7433)..........................  I
Etonitazene (9624).........................  I
Methylphenidate (1724).....................  II
Secobarbital (2315)........................  II
Glutethimide (2550)........................  II
Diprenorphine (9058).......................  II
Oxycodone (9143)...........................  II
Hydromorphone (9150).......................  II
Diphenoxylate (9170).......................  II
Hydrocodone (9193).........................  II
Levomethorphan (9210)......................  II
Levorphanol (9220).........................  II
Meperidine (9230)..........................  II
Metazocine (9240)..........................  II
Methadone (9250)...........................  II
Dextropropoxyphene, bulk (non-dosage forms)  II
 (9273).
Thebaine (9333)............................  II
Levo-alphacetylmethadol (LAAM) (9648)......  II
Oxymorphone (9652).........................  II
------------------------------------------------------------------------

    The firm plans to import small quantities of the listed controlled 
substances to manufacture laboratory reference standards and 
neurochemicals.
    Any manufacturer holding, or applying for, registration as a bulk 
manufacturer of these basic classes of controlled substances may file 
written comments on or objections to the application described above 
and may, at the same time, file a written request for a hearing on such 
application in accordance with 21 CFR 1301.43 in such form as 
prescribed by 21 CFR 1316.47. Any such comments, objections, or 
requests for a hearing may be addressed, in quintuplicate, to the 
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration, United States Department of Justice, 
Washington, DC 20537, Attention: DEA Federal Register Representative 
(CCR), and must be filed no later than (30 days from publication).
    This procedure is to be conducted simultaneously with and 
independent of the procedures described in 21 CFR 1301.34(b), (c), (d), 
(e), and (f). As noted in a previous notice at 40 FR 43745-46 
(September 23, 1975), all applicants for registration to import the 
basic classes of any controlled substances in Schedule I or II are and 
will continue to be required to demonstrate to the Deputy Assistant 
Administrator, Office of Diversion Control, Drug Enforcement 
Administration that the requirements for such registration pursuant to 
21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1301.34(a), (b), (c), 
(d), (e), and (f) are satisfied.

    Dated: May 14, 1999.
John H. King,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 99-13097 Filed 5-24-99; 8:45 am]
BILLING CODE 4410-09-M